Skip to content
FDA approves Arexvy for patients 50–59
On June 7, the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GSK’s Arexvy, making it the first respiratory syncytial […]
FDA approves Arexvy for patients 50–59 Read More »
Health
BIO 2024: PDABs and IRA pose a murky threat to patient access
With the passage of the Inflation Reduction Act (IRA) and the growing number of prescription drug affordability boards (PDABs), patients and the biotech industry
BIO 2024: PDABs and IRA pose a murky threat to patient access Read More »
ARPA-H offers fast, flexible support to biotech startups, panelists tell BIO 2024
Getting government support for a biotech startup no longer need be a slow and painful process, according to staff and fundees of the Advanced
ARPA-H offers fast, flexible support to biotech startups, panelists tell BIO 2024 Read More »
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
BIO 2024: Amgen CEO Robert A. Bradway on the impact of policy on the innovation ecosystem
Founded 44 years ago, Amgen was “created at the dawn of the biotechnology revolution,” said Robert A. Bradway, CEO of Amgen, “when faculty at
Admiral William H. McRaven and BIO CEO John F. Crowley talk hope in biotech
“Biotechnology, that’s a great, big word that just means hope.” That’s what Christopher Reeve said years ago at a BIO International Convention. Little did
Admiral William H. McRaven and BIO CEO John F. Crowley talk hope in biotech Read More »
BIO 2024: Viola Davis and Aaron Lazar share lessons on life and legacy
Viola Davis is a world-renowned actress, writer, and producer, holding the coveted EGOT status in Hollywood (winning an Emmy, Grammy, Oscar, and two Tony
BIO 2024: Viola Davis and Aaron Lazar share lessons on life and legacy Read More »
Biotech needs to polish its message as elections approach, experts say
The pollster pulled no punches: The biopharma industry has a poor public image, and politicians in both parties are ready to back drug price
Biotech needs to polish its message as elections approach, experts say Read More »
Gene therapy is the future of medicine, but payment models have to catch up
Gene therapy is poised to break the stratosphere, providing many rare disease patients with an option out of their diseases. Whether innovations in CAR
Gene therapy is the future of medicine, but payment models have to catch up Read More »
Dr. Jason Kelly: Teaming up to build our bio future
Lately the world is enraptured with AI and its potential to change our lives. AI transforms our digital world—the world of information. But changing lives
Dr. Jason Kelly: Teaming up to build our bio future Read More »